NWBO
Northwest Biotherapeutics, Inc. [NWBO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NWBO Stock Summary
Top 10 Correlated Stocks
NWBO
In the News
NWBO Financial details
Company Rating
-
Market Cap
618.78M
Income
-62.23M
Revenue
1.93M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-9.15
Forward P/E
-
PEG
1.59
P/S
359.78
P/B
-11.32
P/C
-
P/FCF
-14.79
Quick Ratio
0.14
Current Ratio
0.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.99%
Revenue last 5Y
-4.33%
Revenue Q/Q
9.61%
EPS Q/Q
-2.38%
-
-
-
-
SMA20
4.17%
SMA50
-10.71%
SMA100
-10.71%
Inst Own
-
Inst Trans
-
ROA
-256%
ROE
104%
ROC
3.3%
Gross Margin
100%
Oper. Margin
-2809%
Profit Margin
-3865%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4-1.09
52W High
-
52W Low
-
RSI
80.58
Rel Volume
9.5
Avg Volume
1.79M
Volume
16.98M
Perf Week
136.66%
Perf Month
75.28%
Perf Quarter
56.79%
Perf Half Y
58.06%
-
-
-
-
Beta
-0.698
-
-
Volatility
0.08%, 0.05%
Prev Close
24.72%
Price
0.439
Change
72.16%
Company Profile
- Volume Average 1.79M
- Market Capitalization 618.78M
- Employee 25
- CEO Ms. Linda F. Powers J.D.
- Headquarters Bethesda,MD,US
- IPO Date 2001-12-14
-
Website
https://www.nwbio.com 
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
